Drug Profile


Alternative Names: 3 OH TAM; Droloxifene citrate; FK 435; K 060; K 21060E; RP 60850

Latest Information Update: 25 Jan 2000

Price : $50

At a glance

  • Originator Klinge Pharma
  • Developer Klinge Pharma; Ligand Pharmaceuticals; Pfizer
  • Class Antineoplastics; Osteoporosis therapies; Stilbenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Cardiovascular disorders; Male osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 25 Jan 2000 Discontinued-II for Male osteoporosis in USA (PO)
  • 25 Jan 2000 Discontinued-II for Breast cancer prevention in USA (PO)
  • 25 Jan 2000 Discontinued-II for Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top